HC Wainwright Forecasts Reduced Earnings for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities researchers at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for Xeris Biopharma in a report issued on Monday, November 11th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.19 per share for the year, down from their prior forecast of $0.27. HC Wainwright currently has a “Buy” rating and a $6.60 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share.

Separately, Piper Sandler downgraded Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Monday.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $3.15 on Tuesday. The stock’s fifty day moving average is $2.99 and its two-hundred day moving average is $2.53. The firm has a market capitalization of $469.60 million, a P/E ratio of -7.00 and a beta of 2.70. Xeris Biopharma has a fifty-two week low of $1.46 and a fifty-two week high of $3.64.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Xeris Biopharma by 7.3% during the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after buying an additional 519,897 shares during the period. NEA Management Company LLC acquired a new position in Xeris Biopharma during the first quarter worth $926,000. Renaissance Technologies LLC grew its position in shares of Xeris Biopharma by 33.9% in the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after purchasing an additional 342,300 shares during the last quarter. Rosalind Advisors Inc. grew its position in Xeris Biopharma by 10.6% during the second quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock worth $7,020,000 after buying an additional 300,000 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Xeris Biopharma during the third quarter worth about $237,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.